Clinical trial
END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma…
NCT00401635 · National Cancer Institute, Naples, Other · Completed
Key facts
| NCT number | NCT00401635 |
|---|---|
| Title | END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin |
| Official title | Phase II Multicentered Study of First-Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With the Combination of Carboplatin and Liposomal Doxorubicin |
| Lead sponsor | National Cancer Institute, Naples, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Cancer |
| Intervention type | Drug |
| Interventions | liposomal doxorubicin, carboplatin |
| Enrollment | 42 |
| Start date | Nov 1, 2002 |
| First posted | Nov 20, 2006 |
| Last update posted | Sep 5, 2007 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: